Benjamin POIROT

Dr. Benjamin POIROT

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2020 in Experimental and Applied Acarology
Verified
Journal Article
Closed access
PDF file
GAGabrielle Almecija
Gabrielle Almecija
BPBenjamin POIROT
Benjamin POIROT
PCPrecillia Cochard
Precillia Cochard
CSChristelle Suppo
Christelle Suppo

1 January 2021 in Science of The Total Environment
Verified
Journal Article
Closed access
PCPrecillia Cochard
Precillia Cochard
MLMyriam Laurie
Myriam Laurie
BVBruno Veyrand
Bruno Veyrand
BBBruno Le Bizec
Bruno Le Bizec
BPBenjamin POIROT
Benjamin POIROT
PMPhilippe Marchand
Philippe Marchand

14 September 2022 in Pest Management Science
Verified
Journal Article
Open access
GAGabrielle Almecija
Gabrielle Almecija
MSMarion Schimmerling
Marion Schimmerling
ACAurélie Del Cont
Aurélie Del Cont
BPBenjamin POIROT
Benjamin POIROT
VDVeronique Duquesne
Veronique Duquesne
BACKGROUND: Varroa destructor is a parasitic mite of the honey bee, Apis mellifera. Its presence in colonies can lead to a collapse within a few years. The use of acaricides has become essential to manage the hive infestation. However, the repeated and possibly incorrect use of acaricide treatments, as tau‐fluvalinate, has led to the development of resistance. The in vitro phenotypic test allows the proportion of susceptible or resistant individuals to be known following an exposure to an active substance. In Varroa mites, resistance to tau‐fluvalinate is associated with the presence of mutations at the position 925 of the voltage‐gated sodium channel (VGSC).RESULTS: Here, we compared the results obtained with an in vitro phenotypic test against tau‐fluvalinate and those obtained with an allelic discrimination assay on 13 treated and untreated Varroa populations in France. The correlation between the phenotype and the genetic profile rate is found to be 0.89 Varroa mites having resistant phenotypic profile have a probability of 63% to present the L925V mutation (resistance detection reliability). However, 97% of the Varroa mites having the susceptible phenotype do not present the L925V mutation (susceptible detection reliability).CONCLUSION: The L925V mutation explains most of the resistance to tau‐fluvalinate in V. destructor in the populations tested. However, other mutations or types of resistance may also be involved to explain the survival of Varroa mites in the phenotypic test. © 2022 The Authors. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

5 November 2021 in Pest Management Science
Verified
Journal Article
Closed access
PDF file
GAGabrielle Almecija
Gabrielle Almecija
BPBenjamin POIROT
Benjamin POIROT
MVMarie Ventelon
Marie Ventelon
CSChristelle Suppo
Christelle Suppo

30 June 2025 in Inorganic Chemistry Frontiers
Verified
Journal Article
Open access
PDF file
AFArcadie Fuior
Arcadie Fuior
LCLoïc Colin-Duchevet
Loïc Colin-Duchevet
VCValentina Cebotari
Valentina Cebotari
ANAmélie Noël
Amélie Noël
IRIsabelle Ribaud
Isabelle Ribaud
SFSebastien Floquet
Sebastien Floquet
A series of molybdenum coordination complexes, stable, non toxic, easy to handle, which are assimilated by honey bees as feed supplement to improve the health of the colony, decrease the mortality, and increase the honey production.

1 March 2024 in Parasitologia
Verified
Journal Article
Open access
PDF file
GAGabrielle Almecija
Gabrielle Almecija
BPBenjamin POIROT
Benjamin POIROT
PMPaulo Mielgo
Paulo Mielgo
MWMax Watkins
Max Watkins
CSChristelle Suppo
Christelle Suppo
The presence of the Varroa destructor mite requires the use of acaricide treatments for honeybee colonies. Amitraz is one of the most common acaricide-active ingredients used by beekeepers. Certain Varroa mite populations have developed resistance to amitraz, thereby leading to a loss in the efficacy of amitraz-based treatments. Two products, Apivar and Supatraz, were applied in the same apiary in France to evaluate their efficacy. Both treatments are amitraz-based but have different galenics. Thanks to field data, a dynamic model was used to simulate the actions of Apivar and Supatraz on the mite population. We considered two parameters to compare the products as follows: the daily mortality rate and the treatment duration. In the field, the percentage of the efficacy of the two products was not significantly different, but Supatraz kills mites faster and decreases 90% of the mite infestation in 28.4 days compared with 50.9 days when using Apivar. Through modeling, we showed the daily impact of the two different products on mite population. Supatraz has a higher daily mortality rate during the first two weeks than Apivar. Supatraz requires a lower efficacy (% of varroa mites killed during all the treatment) to stabilize the varroa mite population due to its faster release of active ingredients than Apivar, thereby needing a shorter period to achieve the same result. Depending on the model, Supatraz conserves effective efficacy when used against moderately resistant mites (with mite mortality being 40–70% at the LC90) but not against highly resistant mites (with mite mortality being <40% at the LC90). These results show that the comparison of the efficacy of the two products with different characteristics (duration of treatment and daily mortality rate) should be analyzed with caution.